AZD8330 First Time in Man in Patients With Advanced Malignancies

Completed · Phase 1

Conditions studied: Cancer

In brief

The primary purpose of this protocol is to investigate the safety and tolerability of AZD8330 (ARRY-424704) in patients with Advanced Malignancies

Key facts

Study ID

NCT00454090

Run by

AstraZeneca

People needed

83

Starts

2007-03-01

Expected to finish

2011-03-01

Last updated by the study team

2011-08-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cancer which is refractory to standard therapies, or no therapies exist;

You may not qualify if…

• Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start;
• Hasn't participated in investigation drug study within 30 days;
• Brain metastases/spinal cord compression unless treated and stable,
• Off steroids/anticonvulsants.

Where it is running

• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Houston, Texas, United States
• Research Site — Oslo, Norway

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.